Combination Study of Prexasertib and Olaparib in Patients With Advanced Solid Tumors

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Geoffrey Shapiro, MD, PhD
Study ID
NCT03057145
Phase
PHASE1
Status
Completed

Conditions

  • Solid Tumor

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Prexasertib — DRUG
    LY2606368 is a checkpoint kinase 1 (CHK1) inhibitor that is being developed as a treatment for patients with advanced cancer
  • Olaparib — DRUG
    Olaparib is a poly (ADP-ribose) polymerase (PARP) inhibitor.

Study Details

This research study is studying a combination of targeted therapies as a possible treatment for Advanced Solid Tumors. The study interventions involved in this study are: * LY2606368 * Olaparib

Key Dates

Start date
Mar 10, 2017
Status verified
Sep 2021
Primary completion
Feb 25, 2020
Completion
Jun 9, 2021

Study Design

Enrollment
29 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Prexasertib Combine with Olaparib
    * Olaparib will be administered orally on an intermittent schedule during each 28-day cycle. Exact administration schedule will depend on assigned dose level. * Prexasertib will be administered intravenously on Days 1 and 15 of a cycle

Primary Outcome Measure

Maximum Tolerated Dose [ Time Frame: 2 months ]

Locations (1)

FacilityCityStateZIPSite coordinators
Dana Farber Cancer InstituteBostonMassachusetts02215-

Find similar trials in Boston, MA

By research site
Dana Farber Cancer Institute· Boston, MA

Related Studies